$995 | Single User
$1990 | Site License
$2495 | Global License

Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]

Published by FirstWord Pharma: 01 Feb 2016 | 306 | In Stock

Introduction

Introduction


Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Chronic Lymphocytic Leukaemia (CLL). Topics covered include opinions about the use of combinations containing Zydelig (idelalisib; Gilead) or Imbruvica (ibrutinib; AbbVie/Janssen) with chemotherapy, for treating patients with relapsed CLL, and the emergence of the novel targeted therapy venetoclax (ABT-199; Roche/AbbVie) as a potential competitor within the CLL space. Results of the RESONATE-2 and -17 trials and their potential impact on the role of Imbruvica in the first-line CLL setting, are also discussed.


Key Questions Answered in this Update Bulletin:


  • How do KOLs view the results of Study 115 of Gilead’s Zydelig plus bendamustine/Rituxan in relapsed CLL and which patients are considered most suitable for this triple combination?

  • How do KOLs view the role of chemotherapy within the combination of Zydelig plus bendamustine/Rituxan in Study 115?

  • As AbbVie/Janssen’s Imbruvica in combination with bendamustine/Rituxan awaits approval as a treatment for patients with relapsed/refractory CLL, how crucial will its toxicity profile prove for product differentiation?

  • How do KOLs view the design of the RESONATE-2 trial and will the results be sufficient to secure the approval of Imbruvica as a first-line CLL therapy?

  • How will the results of the RESONATE-17 trial affect Imbruvica’s role as a first-line therapy for patients with CLL harbouring the 17p deletion?

  • Can the tumour lysis risk associated with the use of Roche/AbbVie’s venetoclax be effectively managed and thus allow the agent to realise its potential as a successful CLL therapy?

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

    Table of Contents
    for Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]

    • -

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    306 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    Global Chronic Kidney Disease Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    The Outlook for Wearable Health Tech in Managing Chronic Disease
    IntroductionWearable tech – the new golden ticket for patient adherence?Wearable technology is being...
    01 May 2016 by FirstWord Pharma USD $695 More Info
    Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
    IntroductionThis edition presents key opinion leader (KOL) views on recent developments in the chron...
    01 Feb 2016 by FirstWord Pharma USD $995 More Info
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015SummaryGlobalD...
    30 Oct 2015 by Global Data USD $2,500 More Info
    Chronic Lymphocytic Leukaemia: KOL Insight
    IntroductionIn the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s...
    01 Sep 2015 by FirstWord Pharma USD $7,900 More Info
    Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
    IntroductionCombination therapy is set to take centre stage in the treatment of COPD as leading comp...
    20 Apr 2015 by FirstWord Pharma USD $7,900 More Info
    Chronic Lymphocytic Leukaemia: KOL Insight
    IntroductionChronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until rece...
    27 May 2014 by FirstWord Pharma USD $7,900 More Info
    Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
    IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
    20 Jan 2014 by FirstWord Pharma USD $7,495 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • Allied Market Research
    • CBR Pharma
    • Current Partnering
    • Firstword
    • Global Data
    • Global Markets Direct
    • ICD Research
    • Infinti Research Technavio
    • Marketline
    • Markets and Markets
    • Micro Markets Monitor
    • MP Advisors
    • Venture Planning Group
    • GMR Data